Case Western Reserve University

Case Western Reserve University grants exclusive license to Ionis Pharmaceuticals to advance antisense therapy for Pelizaeus-Merzbacher disease

Case Western Reserve University and Ionis Pharmaceuticals Inc. have signed an exclusive license agreement to advance and commercialize a therapeutic approach discovered by university medical ...
MedCity News

Fostering the Next Generation of Antisense Oligonucleotide Therapies

When the drug fomivirsen was approved by the FDA in 1998 for the treatment of cytomegalovirus retinitis in patients with HIV/AIDs, it was hailed as a milestone in drug discovery because it was the ...
BioSpace

Ionis Heads to FDA as Antisense Therapy Aces Pivotal Study in Rare Neurological Disease

By improving gait stability, Ionis’ zilganersen could be “potentially disease modifying,” according to analysts at William ...

EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers

Hoth Therapeutics Inc. (NASDAQ:HOTH) on Tuesday announced combined findings from multiple preclinical programs evaluating its precision antisense candidate HT-KIT. HT-KIT is a precision antisense ...
BioWorld

First-in-class antisense RNA therapy for BK virus presented

Patients receiving a kidney transplant and who are positive for BK virus (BKV) are at risk of losing their transplant due to BKV reactivation. At this time, there are no antiviral options available ...
Nasdaq

Celanese (CE) and Secarna Partner for Antisense Therapies

Celanese Corporation CE and Secarna Pharmaceuticals GmbH & Co. KG recently established a research collaboration to create long-acting implants delivering antisense oligonucleotides ("ASO"). ASOs are ...
BioWorld

CIRM grant supports Cure Rare Disease’s antisense oligonucleotide therapy for SCA3

Cure Rare Disease has been awarded a $5.69 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the development of an antisense oligonucleotide therapy for ...
Business Wire

Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies

DALLAS & MARTINSRIED, Germany--(BUSINESS WIRE)--Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent ...
The Scientist

Making Sense of Antisense

A drug that halts an AIDS-related eye infection could be the first antisense therapy to reach the market. However, whether the drug can truly be called "antisense" depends on some specifics--such as ...
ascopubs.org

Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma

Randomized Cross-Over Trial of Progenitor-Cell Mobilization: High-Dose Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor (G-CSF) Versus Granulocyte-Macrophage Colony-Stimulating Factor Plus ...
Nasdaq

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an ...